Key Takeaways
- Harbour BioMed has formed Solstice Oncology, securing a $105 million upfront deal for HBM4003, a monoclonal antibody.
- The potential total value of the agreement could reach $1.1 billion based on future milestones.
- Harbour focuses on immunology and oncology, leveraging its Harbour Mice platform to develop fully human monoclonal antibodies.
New Deal for HBM4003
Harbour BioMed has taken a significant step by establishing Solstice Oncology, which has signed an exclusive development and commercialization agreement for Harbour’s HBM4003, an anti-CTLA-4 monoclonal heavy chain-only antibody (HCAb). This agreement, however, excludes rights for Greater China.
In this deal, Harbour BioMed will receive an upfront payment package totaling $105 million. This includes $50 million in cash, $5 million in near-term payments, and over $50 million in equity in Solstice Oncology.
Harbour CEO and co-founder Jingsong Wang, M.D., Ph.D., expressed enthusiasm about the partnership, emphasizing the opportunity to build a global biotechnology company alongside accomplished investors. The structure of the agreement is designed to foster long-term value creation while allowing Harbour to engage actively in the global development of HBM4003.
In addition to the upfront payments, Harbour BioMed stands to gain up to $1.1 billion in biobucks tied to the completion of specific future milestones, alongside tiered royalties on sales outside of China.
While the deal did not specify the therapeutic area Solstice will target for HBM4003, it can be inferred that the focus will be on oncology, given the company’s name and the mechanism of the treatment.
Harbour BioMed primarily concentrates on both immunology and oncology development, utilizing its proprietary Harbour Mice platform to create fully human monoclonal antibodies in these critical areas. The company, headquartered in Shanghai, also has a significant presence in Cambridge, Massachusetts, and Rotterdam, the Netherlands. In December, Harbour announced a partnership with Bristol Myers Squibb, which potentially included biobucks up to $1.035 billion for several discovery programs.
The content above is a summary. For more details, see the source article.